NDC 43624-002

Halaven

Eribulin Mesylate

Halaven is a Intravenous Injection in the Human Prescription Drug category. It is labeled and distributed by Bsp Pharmaceuticals Spa. The primary component is Eribulin Mesylate.

Product ID43624-002_011afacd-c29f-4808-b38f-f113c1bb2717
NDC43624-002
Product TypeHuman Prescription Drug
Proprietary NameHalaven
Generic NameEribulin Mesylate
Dosage FormInjection
Route of AdministrationINTRAVENOUS
Marketing Start Date2017-04-21
Marketing CategoryNDA / NDA
Application NumberNDA201532
Labeler NameBSP Pharmaceuticals SpA
Substance NameERIBULIN MESYLATE
Active Ingredient Strength1 mg/mL
Pharm ClassesMicrotubule Inhibition [PE],Microtubule Inhibitor [EPC]
NDC Exclude FlagN
Listing Certified Through2021-12-31

Packaging

NDC 43624-002-01

100 TRAY in 1 BOX, UNIT-DOSE (43624-002-01) > 3 mL in 1 TRAY
Marketing Start Date2017-04-21
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 43624-002-01 [43624000201]

Halaven INJECTION
Marketing CategoryNDA
Application NumberNDA201532
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2017-04-21

Drug Details

Active Ingredients

IngredientStrength
ERIBULIN MESYLATE.5 mg/mL

OpenFDA Data

SPL SET ID:8fc8fe1d-59fe-4e43-a95c-e7aa13422cd6
Manufacturer
UNII
RxNorm Concept Unique ID - RxCUI
  • 1045456
  • 1045460
  • Pharmacological Class

    • Microtubule Inhibition [PE]
    • Microtubule Inhibitor [EPC]

    NDC Crossover Matching brand name "Halaven" or generic name "Eribulin Mesylate"

    NDCBrand NameGeneric Name
    43624-002Halaveneribulin mesylate
    62856-389Halaveneribulin mesylate

    Trademark Results [Halaven]

    Mark Image

    Registration | Serial
    Company
    Trademark
    Application Date
    HALAVEN
    HALAVEN
    77886054 not registered Dead/Abandoned
    Eisai R&D Management Co., Ltd.
    2009-12-04
    HALAVEN
    HALAVEN
    77097283 3962019 Live/Registered
    Eisai R&D Management Co., Ltd.
    2007-02-01

    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.